For XPA, subjects with homozygous wild-type genotypes and high arsenic (> 0.286 μg/g) had an elevated risk for BCC compared with the homozygous wild-type with lower arsenic (XPA: OR = 1.8; 95% CI, 0.9–3.7), although the test for interaction was not statistically significant (p = 0.24). Here, XPA is linked to skin basal cell carcinoma.